VAXART INC. VXRT — Up 128.9%
Vaxart is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Its development programs are oral tablet vaccines designed to provide protection against norovirus, seasonal influenza and respiratory syncytial virus. It also acts as a therapeutic vaccine for human papillomavirus.
No wonder, the company is in an advantageous position now as all expect a COVID-19 vaccine from it. It surged 49.7% on Feb 27. The stock has a Zacks Rank
#2 andcomes from a favorable Zacks industry (top 39%).
finance.yahoo.com/news/...tion-5-stocks-resist-144302822.html